180 related articles for article (PubMed ID: 35008323)
1. PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
Khan HY; Uddin MH; Balasubramanian SK; Sulaiman N; Iqbal M; Chaker M; Aboukameel A; Li Y; Senapedis W; Baloglu E; Mohammad RM; Zonder J; Azmi AS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008323
[TBL] [Abstract][Full Text] [Related]
2. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W; Baloglu E; Li J; Dyson G; Xue Y; El-Rayes B; Azmi AS
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795447
[TBL] [Abstract][Full Text] [Related]
3. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
4. Targeting the vulnerability to NAD
Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
[TBL] [Abstract][Full Text] [Related]
5. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
6. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
[TBL] [Abstract][Full Text] [Related]
7. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Mitchell S; Zhang P; Cannon M; Beaver L; Lehman A; Harrington B; Sampath D; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jun; 14(1):101. PubMed ID: 34187548
[TBL] [Abstract][Full Text] [Related]
9. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
10. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell Lymphoma Cells].
Zhang YL; Chen YH; Zheng RJ; Zheng KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):470-475. PubMed ID: 38660854
[TBL] [Abstract][Full Text] [Related]
14. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH; Hastrup N; Sehested M
APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.
Levi E; Zhang L; Aboukameel A; Rishi S; Mohammad RM; Polin L; Hatfield JS; Rishi AK
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1401-13. PubMed ID: 20809119
[TBL] [Abstract][Full Text] [Related]
19. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.
Sekihara K; Saitoh K; Han L; Ciurea S; Yamamoto S; Kikkawa M; Kazuno S; Taka H; Kaga N; Arai H; Miida T; Andreeff M; Konopleva M; Tabe Y
Oncotarget; 2017 May; 8(21):34552-34564. PubMed ID: 28388555
[TBL] [Abstract][Full Text] [Related]
20. Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.
Schmitz R; Renné C; Rosenquist R; Tinguely M; Distler V; Menestrina F; Lestani M; Stankovic T; Austen B; Bräuninger A; Hansmann ML; Küppers R
Leukemia; 2005 Aug; 19(8):1452-8. PubMed ID: 15973455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
